

Received: 11/16/10  
First Name: Preetha  
Last Name: Rajaraman  
Institution: Division of Cancer Epidemiology and Genetics, National Cancer Institute  
Address 1: 6120 Executive Blvd  
Address 2:  
City: Rockville  
State/Province: MD  
Country: USA  
Zip: 20852  
Phone: 301-496-8847  
Alternate Phone:  
Email: rajarama@mail.nih.gov

---

Requirements to submit AOI:

---

A comprehensive review of previously published data has been completed.: Yes  
The specific aims are clear and focused.: Yes  
The investigator has appropriate experience and expertise to develop the concept proposal; if not, has identified a mentor or senior co-investigator.: Yes  
The investigator agrees to develop an initial draft of the concept proposal within 6 weeks of approval of the AOI and to finalize the concept proposal within 6 months.: Yes

---

Project Title: Radiation dose and risk of meningioma in the Childhood Cancer Survivor Study: Analysis of radiation dose-response and its modifiers.  
Planned research population (eligibility criteria): Cases: individuals with second or subsequent meningioma in the CCSS Controls: individually matched with no subsequent cancer from the CCSS  
Proposed specific aims: a)Describe the risk of meningioma in relation to radiation dose to the tumor site (or comparable location in matched controls) among members of the CCSS cohort b)Explore potential factors that may modify the risk of meningioma in relation to radiation treatment. c)Describe the risk of meningioma in relation to chemotherapeutic treatments. Effect of chemotherapy on risk of meningioma can only be observed among patients not exposed to radiotherapy or those who received lower radiation dose.  
Will the project require non-CCSS funding to complete?: No  
If yes, what would be the anticipated source(s) and timeline(s) for securing funding?:

---

Does this project require contact of CCSS study subjects for . . .

---

Additional self-reported information: No  
Biological Samples: No  
Medical record data: No  
If yes to any of the above, please briefly describe.:

---

What CCSS Working Group(s) would likely be involved? (Check all that apply)

---

Second Malignancy: Primary  
Chronic Disease:  
Psychology / Neuropsychology:  
Genetics:  
Cancer Control:  
Epidemiology / Biostatistics: Secondary

---

To describe the anticipated scope of the study, please indicate the specific CCSS data to be included as outcome (primary or secondary) or correlative factors. (Check all that apply)

---

Late mortality:  
Second Malignancy: Primary

---

Health Behaviors

---

Tobacco: Correlative Factors  
Alcohol: Correlative Factors  
Physical activity:  
Medical screening:  
Other:  
If other, please specify:

---

Psychosocial

---

Insurance:  
Marriage: Correlative Factors  
Education: Correlative Factors  
Employment:  
Other:  
If other, please specify:

---

Medical conditions

---

Hearing/Vision/Speech:  
Hormonal systems: Secondary  
Heart and vascular:  
Respiratory:  
Digestive:  
Surgical procedures:  
Brain and nervous system:  
Other:  
If other, please specify:

---

Medications

---

Describe medications: oral contraceptives; hormone replacement therapy

---

Pregnancy and offspring: Secondary  
Family History: Secondary

---

Psychologic/Quality of Life

---

BSI-18:  
SF-36:  
CCSS-NCQ:  
PTS:  
PTG:  
Other:  
If other, please specify:

---

Chronic conditions (CTCAE v3):  
Health status:

---

Demographic

---

Age: Correlative Factors  
Race: Correlative Factors  
Sex: Correlative Factors  
Others:  
If others, please specify:

---

Cancer treatment

---

Chemotherapy: Correlative Factors  
Radiation therapy: Correlative Factors  
Surgery:

---

Anticipated sources of statistical support

---

CCSS Statistical Center: Yes  
Local institutional statistician: Yes  
If local, please provide the name(s) and contact information of the statistician(s) to be involved.: Gila Neta netag@mail.nih.gov Preetha Rajaraman rajarama@mail.nih.gov  
Peter Inskip inskippe@mail.nih.gov  
Will this project utilize CCSS biologic samples?: No

---

If yes, which of the following?

---

Buccal cell DNA:

Peripheral blood:

Lymphoblastoid cell lines:

Second malignancy pathology samples:

Other requiring collection of samples:

If other, please explain:

---

---

Other general comments: